Yu Shen, PhD.

Peer-Reviewed Articles

1. Wanis, K, Dong, W, Shen, Y, Meric-Bernstam, F, Adesoye, T, Kuerer, HM, Caudle, AS, Tamirisa, N, DeSnyder, SM, Sun, SX, Bedrosian, I, Singh, P, Cox, SE, Hunt, KK, Hwang, RF. Predicting pathologic ≥N2 disease in women with breast cancer. npj Breast Cancer 11(1), 2025. e-Pub 2025. PMID: 40404657.
2. Iwase T, Sridhar N, Kai M, Dong W, Shen Y, Krishnamurthy S, Lucci A, Le-Petross HTC, Nasrazadani A, Saleem S, Layman RM, Valero V, Tripathy D, Woodward WA, Cheng YC, Nakhlis F, Bellon JR, Lynce F, Ueno NT. Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer: a multicenter retrospective study. Breast Cancer Res Treat, 2025. e-Pub 2025. PMID: 40753318.
3. Qin J, Piao J, Ning J, Shen Y. Conformal predictiv intervals in survival analysis: a resampling approach. Biometrics 81(2), 2025. e-Pub 2025.
4. Wanis, K, Mitchell, MP, Giordano, SH, Litton, J, Shaitelman, SF, Tamirisa, N, Bedrosian, I, Dong, W, Shen, Y, Hunt, KK, Singh, P, Sun, SX, Caudle, AS, Kuerer, HM, Meric-Bernstam, F, Hwang, RF, Adesoye, T. Implications of omitting sentinel lymph node biopsy on adjuvant decision making for patients with small breast cancers. Cancer 131(11), 2025. e-Pub 2025. PMID: 40433858.
5. Kuerer HM, Valero V, Smith BD, Krishnamurthy S, Diego EJ, Johnson HM, Lin H, Shen Y, Lucci A, Shaitelman SF, Mitchell MP, Boughey JC, White RL, Hunt KK, Yang WT, Rauch GM. Selective Elimination of Breast Surgery for Invasive Breast Cancer: A Nonrandomized Clinical Trial. JAMA Oncol 11(5):529-534, 2025. e-Pub 2025. PMID: 40152443.
6. Wanis KN, Dong W, Shen Y, Bernstam FM, Adesoye T, Kuerer HM, Caudle AS, Tamirisa N, DeSnyder SM, Sun SX, Bedrosian I, Singh P, Cox SE, Hunt KK, Hwang RF. Predicting pathologic ≥N2 disease in women with breast cancer. npj Breast Cancer 11(46), 2025. e-Pub 2025.
7. Wanis KN, Mitchell MP, Giordano SH, Litton JK, Shaitelman SF, Tamirisa N, Bedrosian I, Dong W, Shen Y, Hunt KK, Singh P, Sun SX, Caudle AS, Kuerer HM, Meric-Bernstam F, Hwang RF, Adesoye T. Implications of omitting sentinel lymph node biopsy on adjuvant decision making for patients with small breast cancers. Cancer, 2025. e-Pub 2025.
8. Tamirisa, N, Dong, W, Shen, Y, Lin, Y, Shaitelman, SF, Babiera, G, Bedrosian, I. Sequence of therapy impact on older women with comorbidities and triple-negative or HER2-positive breast cancer. npj Breast Cancer 11(1), 2025. e-Pub 2025. PMID: 39987164.
9. Goswami S, Gao J, Basu S, Shapiro DD, Karam JA, Tidwell RS, Ahrar K, Campbell MT, Shen Y, Trevino AE, Mayer AT, Espejo AB, Seua C, Macaluso MD, Chen Y, Liu W, He Z, Yadav SS, Wang Y, Rao P, Zhao L, Zhang J, Jindal S, Tannir NM, Futreal A, Wang L, Sharma P. Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trial. Nat Commun 16(1):1846, 2025. e-Pub 2025. PMID: 39984485.
10. Dong W, Fujii T, Ning J, Iwase T, Qin J, Ueno NT, Shen Y. Reassessing Estrogen Receptor Expression Thresholds for Breast Cancer Prognosis in HER2-negative Patients Using Shape Restricted Modeling. Scientific Reports 15(1), 2025. e-Pub 2025. PMID: 39955419.
11. Raghavendra AS, Kettner NM, Kwiatkowski D, Damodaran S, Wang Y, Ramirez D, Gombos DS, Hunt KK, Shen Y, Keyomarsi K, Tripathy D. Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+/HER2- breast cancer. NPJ Breast Cancer 11(1):7, 2025. e-Pub 2025. PMID: 39865083.
12. Xie C, Huang X, Li R, Shen Y, Short NJ, Bhalla KN, M Kantarjian AH. A New Cure Model Accounting for Longitudinal Data and Flexible Patterns of Hazard Ratios Over Time. Statistical Methods in Medical Research. e-Pub 2025.
13. Michell M, Shaitelman S, Smith BD, Krishnamurthy S, Valero V, Rauch GM, Shen Y, Lin H, Kuerer HM. Feasibility of breast conserving surgery alone in HER2-positive exceptional responders to neoadjuvant systemic therapy. European Journal of Surgical Oncology 50(12), 2024. PMID: 39243728.
14. Irajizad E, Fahrmann JF, Toumazis I, Vykoukal J, Dennison JB, Shen Y, Do K, Ostrin EJ, Feng Z, Hanash S. Biomarker trajectory for earlier detection of lung cancer. eBioMedicine 108, 2024. e-Pub 2024. PMID: 39353277.
15. Chen Z, Shen Y, Qin J, Ning J. Likelihood Adaptively Incorporated External Aggregate Information with Uncertainty for Survival Data. Biometrics 80(4), 2024. e-Pub 2024. PMID: 39468742.
16. Poli EC, Dong W, Shaitelman SF, Tamirisa N, Shen Y, Bedrosian I. Survival outcomes after omission of surgery for ductal carcinoma in situ. NPJ Breast Cancer 10(1):82, 2024. e-Pub 2024. PMID: 39304662.
17. Singareeka Raghavendra, A, Liu, D, Shen, Y, Barcenas, CH, Ueno, NT, Giordano, SH, Tripathy, D, Karuturi, MS. Outcomes of older adults with early-stage triple-negative breast cancer (TNBC) receiving chemotherapy. Breast Cancer Research and Treatment 207(1):81-90, 2024. e-Pub 2024. PMID: 38916821.
18. Ishizawa, Sayaka, Niu J, Tammemagi MC, Irajizad E, Shen Y, Lu KH, Meyer LA, Toumazis AI. Estimating sojourn time and sensitivity of screening for ovarian cancer using a Bayesian framework. JNCI 116(11):1798-1844, 2024. e-Pub 2024. PMID: 39038822.
19. Iwase, T, Cohen, E, Gao, H, Alexander, A, Kai, M, Chiv, VY, Wang, X, Krishnamurthy, S, Liu, D, Shen, Y, Kida, K, Reuben, A, Layman, RM, Ramirez, DL, Tripathy, D, Moulder, S, Yam, C, Valero, V, Lim, B, Reuben, JM, Ueno, NT. Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy. Clinical Cancer Research 30(11):2424-2432, 2024. e-Pub 2024. PMID: 38629963.
20. Diao, K, Lei, X, He, W, Jagsi, R, Giordano, SH, Smith, GL, Caudle, AS, Shen, Y, Peterson, SK, Smith, B. Racial and Ethnic Differences in Long-Term Adverse Radiation Therapy Effects Among Breast Cancer Survivors. International Journal of Radiation Oncology Biology Physics 118(3):626-631, 2024. e-Pub 2024. PMID: 37751792.
21. Mouabbi, JA, Qaio, W, Shen, Y, Singareeka Raghavendra, A, Tripathy, D, Layman, RM. Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma. Oncologist 29(3):213-218, 2024. e-Pub 2024. PMID: 38070191.
22. Wang, S, Ning, J, Xu, Y, Shih, YT, Shen, Y, Li, L. Longitudinal varying coefficient single-index model with censored covariates. Biometrics 80(1), 2024. e-Pub 2024. PMID: 38364803.
23. Iwase T, Parikh A, Dong W, Shen Y, Adams DL, Tang C, Evan N, Cohen, Reuben JM, Shrimanker TV, Chainitikun S, Kida K, Akshara, Raghavendra S, Sapon ME, Sahin O, James A, Sridhar N, Ann H, Klopp, Tripathy D, T Ueno AN. Circulating cancer-associated macrophage-like cells and macrophage-related cytokines in obese patients with advanced breast cancer who undergo neoadjuvant chemotherapy. Journal of Cancer. e-Pub 2024.
24. Long, JP, Shen, Y. Detection method has independent prognostic significance in the PLCO lung screening trial. Scientific reports 13(1), 2023. e-Pub 2023. PMID: 37591907.
25. Diao K, Lei X, He W, Jagsi R, Giordano SH, Smith GL, Caudle A, Shen Y, Peterson S, Smith BD. Patient-Reported Quality of Life after Breast Conserving Surgery with Radiotherapy versus Mastectomy and Reconstruction. Ann Surg 278(5):E1096-E1102, 2023. e-Pub 2023. PMID: 37232937.
26. Zaveri S, Everidge S, FitzSullivan E, Hwang R, Smith BD, Lin H, Shen Y, Lucci A, Teshome M, Sun SX, Hunt KK, Kuerer HM. Extremely Low Incidence of Local-Regional Recurrences Observed Among T1-2 N1 (1 or 2 Positive SLNs) Breast Cancer Patients Receiving Upfront Mastectomy Without Completion Axillary Node Dissection. Ann Surg Oncol 30(12):7015-7025, 2023. e-Pub 2023. PMID: 37458948.
27. Yang, L, Lin, Y, Shen, Y, Roy, M, Albarracin, C, Ding, Q, Huo, L, Chen, H, Wei, B, Bu, H, Bedrosian, I, Wu, Y. Clinical outcome and therapeutic impact on neuroendocrine neoplasms of the breast. Breast Cancer Research and Treatment 202(1):23-32, 2023. e-Pub 2023. PMID: 37566192.
28. Pak D, Ning J, Kryscio RJ, Shen Y. Evaluation of the natural history of disease by combining incident and prevalent cohorts: application to the Nun Study. Lifetime Data Anal 29(4):1-17, 2023. e-Pub 2023. PMID: 37210470.
29. Liu, Y, Wang, S, Li, L, Xu, Y, Shen, Y, Shih, YT. Comparisons of Medical Cost Trajectories Between Non-Hispanic Black and Non-Hispanic White Patients With Newly Diagnosed Localized Prostate Cancer. Value in Health 26(10):1444-1452, 2023. e-Pub 2023. PMID: 37348833.
30. Johnson, HM, Lin, Y, Shen, Y, Diego, EJ, Krishnamurthy, S, Yang, WT, Smith, BD, Valero, V, Lucci, A, Sun, SX, Shaitelman, SF, Mitchell, MP, Boughey, JC, White, RL, Rauch, GM, Kuerer, HM. Patient-Reported Outcomes of Omission of Breast Surgery Following Neoadjuvant Systemic Therapy. JAMA Network Open 6(9):E2333933, 2023. e-Pub 2023. PMID: 37707811.
31. Dohopolski MJ, Diao K, Hutcheson KA, Akhave NS, Goepfert RP, He W, Lei XJ, Peterson SK, Shen Y, Sumer BD, Smith BD, Sher DJ. Long-term Patient-Reported Outcomes in a Population-Based Cohort Following Radiotherapy vs Surgery for Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg 149(8):697-707, 2023. e-Pub 2023. PMID: 37382943.
32. Bree KK, Kokorovic A, Westerman ME, Hensley PJ, Brooks NA, Qiao W, Shen Y, Kamat AM, Dinney CP, Navai N. Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply. J Urol 210(2):101097JU0000000000003553, 2023. e-Pub 2023. PMID: 37211780.
33. Zaveri S, Shlermine E, FitzSullivan E, Hwang R, Smith, BD, Lin HY, Shen Y, Lucci A, Teshome M, Sun SX, Hunt KK, Kuerer HM. Extremely Low Incidence of Local-Regional Recurrences Observed Among T1-2 N1 (1 or 2 Positive SLNs) Breast Cancer Patients Receiving Upfront Mastectomy Without Completion Axillary Node Dissection. Annals of Surgical Oncology, 2023. e-Pub 2023.
34. Xie, X, Chauhan, GB, Edupuganti, R, Kogawa, T, Park, J, Tacam, MJ, Tan, A, Mughees, M, Vidhu, F, Liu, D, Taliaferro, JM, Pitner, MK, Browning, JL, Lee, HJ, Shen, Y, Wang, J, Ueno, NT, Krishnamurthy, S, Hortobagyi, GN, Tripathy, D, Van Laere, SJ, Bartholomeusz, G, Dalby, KN, Bartholomeusz, C. Maternal Embryonic Leucine Zipper Kinase is Associated with Metastasis in Triple-negative Breast Cancer. Cancer Research Communications 3(6):1078-1092, 2023. e-Pub 2023. PMID: 37377604.
35. Li Z, Shen Y, Ning J. Accommodating time-varying heterogeneity in risk estimation under the Cox model: a transfer learning approach. J Am Stat Assoc, 2023. e-Pub 2023. PMID: 38505403.
36. Wang SK, Shen Y, Shih TYC, Xu Y, Li L. Statistical Modeling of Longitudinal Medical Cost Trajectory: Renal Cell Cancer Care Cost Analyse. Biostistics 24(2):244-261, 2023. e-Pub 2023. PMID: 34269395.
37. Smith-Graziani DJ, Parker PA, Peterson SK, Bedrosian I, Shen Y, Black DM, DeSnyder SM, Hunt KK, Dong W, Brewster AM. Prospective Study of Pain Outcomes Associated with Breast Surgery in Women with Nonhereditary Breast Cancer. Ann Surg 277(3):E617-E623, 2023. e-Pub 2021. PMID: 33938495.
38. Li M, Liao K, Chen AJ, Cascone T, Shen Y, Lu Q, Shih YT. Disparity in checkpoint inhibitor utilization among commercially insured adult patients with metastatic lung cancer. J Natl Cancer Inst 115(3):295-302, 2023. e-Pub 2023. PMID: 36346180.
39. Johnson HM, Valero V, Yang WT, Smith BD, Krishnamurthy S, Shen Y, Lin H, Lucci A, Rauch GM, Kuerer HM. Eliminating breast surgery for invasive cancer with exceptional response to neoadjuvant systemic therapy: Prospective multicenter clinical trial planned initial feasibility endpoint. J Am Coll Surg. e-Pub 2023. PMID: 36856291.
40. Cohen EN, Jayachandran G, Gao H, Peabody P, McBride HB, Alvarez FD, Kai M, Song J, Shen Y, Willey JS, Lim B, Valero V, Ueno NT, Reuben JM. Phenotypic Plasticity in Circulating Tumor Cells Is Associated with Poor Response to Therapy in Metastatic Breast Cancer Patients. Cancers (Basel) 15(5), 2023. e-Pub 2023. PMID: 36900406.
41. Wang, S, Ning, J, Xu, Y, Shih, YT, Shen, Y, Li, L. AN EXTENSION OF ESTIMATING EQUATIONS TO MODEL LONGITUDINAL MEDICAL COST TRAJECTORY WITH MEDICARE CLAIMS DATA LINKED TO SEER CANCER REGISTRY. Annals of Applied Statistics 17(1):881-899, 2023. e-Pub 2023.
42. Wang S, Ning J, Xu Y, Shih YT, Shen Y, Li L. Statistical Modeling of Longitudinal Medical Cost Trajectory with Insurance Claims Data. Annals of Applied Statistics 17(1):881-899, 2023. e-Pub 2023.
43. Xie X, Chauhan GB, Edupuganti R, Kogawa T, Park J, Tacam MJ, Mohd M, Shama V, Liu D, Taliaferro JM, Pitner MK, Shen Y, Wang J, Ueno NT, Krishnamurthy S, Hortobagyi GN, Tripathy D, Van Laere S, Bartholomeusz G, Dalby KN. Maternal embryonic leucine zipper kinase is associated with metastasis in triple-negative breast cancer. Cancer Research Communications. e-Pub 2023.
44. Bree KK, Kokorovic A, Westerman ME, Hensley PJ, Brooks NA, Qiao W, Shen Y, Kamat AM, Dinney CP, Navai N. Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy is Prognostic but Not Therapeutic. J Urol 209(1):140-149, 2023. e-Pub 2023. PMID: 36250944.
45. Shen, Y, Ning, J, Lin, Y, Shaitelman, SF, Kuerer, HM, Bedrosian, I. Effectiveness Without Efficacy: Cautionary Tale from a Landmark Breast Cancer Randomized Controlled Trial. Journal of Cancer 14(2):193-199, 2023. e-Pub 2023. PMID: 36741254.
46. Kuerer HM, Smith BD, Krishnamurthy S, Yang WT, Valero V, Shen Y, Lin H, Lucci A, Boughey JC, White RL, Diego EJ, Rauch GM, Trials Group ERC. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. Lancet Oncol 23(12):1517-1524, 2022. e-Pub 2022. PMID: 36306810.
47. Cortés Martínez J, Pak D, Abelenda-Alonso G, Langohr K, Ning J, Rombauts A, Colom M, Shen Y, Gómez Melis G. SARS-Cov-2 incubation period according to vaccination status during the fifth COVID-19 wave in a tertiary-care center in Spain: a cohort study. BMC Infect Dis 22(1):828, 2022. e-Pub 2022. PMID: 36352359.
48. Zhu H, Lan Y, Ning J, Shen Y. Semiparametric copula-based regression modeling of semi-competing risks data. Communications in Statistics – Theory and Methods 51(22):7830–7845, 2022. e-Pub 2022.
49. Elmore LC, Li M, Lin H, Shen Y, Shaitelman SF, Babiera G, Tamirisa N, Bedrosian I. Impact of Medicaid Expansion Under the Affordable Care Act on Receipt of Surgery for Breast Cancer. Ann Surg Open 3(3):e194, 2022. e-Pub 2022. PMID: 36199482.
50. Hernandez S, Parra ER, Uraoka N, Tang X, Shen Y, Qiao W, Jiang M, Zhang S, Mino B, Lu W, Pandurengan R, Haymaker C, Affolter K, Scaife CL, Yip-Schneider M, Schmidt CM, Firpo MA, Mulvihill SJ, Koay EJ, Wang H, Wistuba II, Maitra A, Solis LM, Sen S. Diminished Immune Surveillance during Histologic Progression of Intraductal Papillary Mucinous Neoplasms Offers a Therapeutic Opportunity for Cancer Interception. Clin Cancer Res 28(9):1938-1947, 2022. e-Pub 2022. PMID: 35491652.
51. Chapman BV, Liu D, Shen Y, Olamigoke OO, Lakomy DS, Barrera AMG, Stecklein SR, Sawakuchi GO, Bright SJ, Bedrosian I, Litton JK, Smith BD, Woodward WA, Perkins GH, Hoffman KE, Stauder MC, Strom EA, Arun BK, Shaitelman SF. Breast Radiation Therapy-Related Treatment Outcomes in Patients With or Without Germline Mutations on Multigene Panel Testing. Int J Radiat Oncol Biol Phys 112(2):437-444, 2022. e-Pub 2022. PMID: 34582940.
52. Chapman BV, Liu D, Shen Y, Olamigoke OO, Lakomy DS, Barrera AMG, Stecklein SR, Sawakuchi GO, Bright SJ, Bedrosian I, Litton JK, Smith BD, Woodward WA, Perkins GH, Hoffman KE, Stauder MC, Strom EA, Arun BK, Shaitelman SF. Outcomes After Breast Radiation Therapy in a Diverse Patient Cohort With a Germline BRCA1/2 Mutation. Int J Radiat Oncol Biol Phys 112(2):426-436, 2022. e-Pub 2022. PMID: 34610390.
53. Ha MJ, Singareeka Raghavendra A, Kettner NM, Qiao W, Damodaran S, Layman RM, Hunt KK, Shen Y, Tripathy D, Keyomarsi K. Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study. Int J Cancer 150(12):2025-2037, 2022. e-Pub 2022. PMID: 35133007.
54. Kai M, Marx AN, Liu DD, Shen Y, Gao H, Reuben JM, Whitman G, Krishnamurthy S, Ross MI, Litton JK, Lim B, Ibrahim N, Kogawa T, Ueno NT. A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer. Sci Rep 11(1):22242, 2021. e-Pub 2021. PMID: 34782633.
55. Chen Z, Ning J, Shen Y, Qin J. Combining primary cohort data with external aggregate information without assuming comparability. Biometrics 77(3):1024-1036, 2021. e-Pub 2021. PMID: 32827153.
56. Balema W, Liu D, Shen Y, El-Zein R, Debeb BG, Kai M, Overmoyer B, Miller KD, Le-Petross HT, Ueno NT, Woodward WA. Inflammatory breast cancer appearance at presentation is associated with overall survival. Cancer Med 10(18):6261-6272, 2021. e-Pub 2021. PMID: 34327874.
57. Bree K, Brook NA, Hensley PJ, Lobo N, Xiao L, Shen Y, Navai N, Grossman HB, Dinney CP, Kamat AM. A Novel Nomogram to Predict BCG Response in Patients with High-Grade Non-Muscle Invasive Bladder Cancer. Journal of Urology, 2021. e-Pub 2021.
58. Qin, J, Deng, G, Ning, J, Yuan, A, Shen, Y. Estrogen receptor expression on breast cancer patients’ survival under shape-restricted cox regression model. Annals of Applied Statistics 15(3):1291-1307, 2021. e-Pub 2021. PMID: 34745408.
59. Simons JM, Scoggins ME, Kuerer HM, Krishnamurthy S, Yang WT, Sahin AA, Shen Y, Lin H, Bedrosian I, Mittendorf EA, Thompson A, Lane DL, Hunt KK, Caudle AS. Prospective Registry Trial Assessing the Use of Magnetic Seeds to Localize Clipped Nodes after Neoadjuvant Chemotherapy in Breast Cancer Patients. Ann Surg Oncol 28(8):4277-4283, 2021. e-Pub 2021. PMID: 33417121.
60. Bofill Roig M, Shen Y, Gómez Melis G. Design of phase III trials with long-term survival outcomes based on short-term binary results. Stat Med 40(18):4122-4135, 2021. e-Pub 2021. PMID: 33942352.
61. Boyce-Fappiano D, Bedrosian I, Shen Y, Lin H, Gjyshi O, Yoder A, Shaitelman SF, Woodward WA. Evaluation of Overall Survival and Barriers to Surgery for Patients with Breast Cancer Treated without Surgery: A National Cancer Data Base Analysis. NPJ Breast Cancer 7(1):87, 2021. e-Pub 2021. PMID: 34226566.
62. Brooks NA, Kokorovic A, Xiao L, Matulay JT, Li R, Ranasinghe WKB, Nagaraju S, Shen Y, Gao J, Navai N, Dinney CPN, Grossman HB, Kamat AM. The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin. BJU Int 128(1):65–71, 2021. e-Pub 2021. PMID: 33210440.
63. Tamirisa N, Lin H, Shen Y, Shaitelman SF, Karuturi MS, Giordano SH, Babiera GV, Bedrosian I. Impact of adjuvant endocrine therapy in older patients with comorbidities and estrogen receptor-positive, node-negative breast cancer-a National Cancer Database analysis. Cancer 127(13):2196-2203, 2021. e-Pub 2021. PMID: 33735487.
64. Etzioni R, Shen Y, Shih YT. Identifying Preferred Breast Cancer Risk Predictors: A Holistic Perspective. J Natl Cancer Inst 113(6):660-661, 2021. e-Pub 2020. PMID: 33301010.
65. Semaan A, Bernard V, Kim DU, Lee JJ, Huang J, Kamyabi N, Stephens BM, Qiao W, Varadhachary GR, Katz MH, Shen Y, San Lucas FA, Gascoyne P, Alvarez HA, Maitra A, Guerrero PA. Characterisation of circulating tumour cell phenotypes identifies a partial-EMT sub-population for clinical stratification of pancreatic cancer. Br J Cancer 124(12):1970-1977, 2021. e-Pub 2021. PMID: 33785875.
66. Shih YT, Dong W, Xu Y, Etzioni R, Shen Y. Incorporating Baseline Breast Density When Screening Women at Average Risk for Breast Cancer: A Cost-Effectiveness Analysis. Ann Intern Med 174(5):602-612, 2021. e-Pub 2021. PMID: 33556275.
67. Iwase T, Shrimanker TV, Rodriguez-Bautista R, Sahin O, James A, Wu J, Shen Y, Ueno NT. Changes in overall survival over time for patients with de novo metastatic breast cancer. Cancers (Basel) 13(11), 2021. e-Pub 2021. PMID: 34071219.
68. Yang L, Roy M, Lin H, Shen Y, Abarracin C, Huo L, Chen H, Wei B, Bedrosian I, Bu H, Wu Y. Validation of Prognostic Significance of the Proposed Uniform Classification Framework in Neuroendocrine Neoplasms of the Breast. Breast Cancer Res Treat 186(2):403-415, 2021. e-Pub 2021. PMID: 33528758.
69. Iwase T, Parikh A, Dibaj SS, Shen Y, Shrimanker TV, Chainitikun S, Kida K, Sapon ME, Sahin O, James A, Medrano AYD, Klopp AH, Ueno NT. The Prognostic Impact of Body Composition for Locally Advanced Breast Cancer Patients Who Received Neoadjuvant Chemotherapy. Cancers (Basel) 13(4):1-11, 2021. e-Pub 2021. PMID: 33557032.
70. Pak D, Liu J, Ning J, Gómez G, Shen Y. Analyzing left-truncated and right-censored infectious disease cohort data with interval-censored infection onset. Stat Med 40(2):287-298, 2021. e-Pub 2021. PMID: 33086432.
71. Harun, N, Cai, B, Shen, Y. A Bayesian semiparametric method for analyzing length-biased data. Journal of Applied Statistics 48(6):977-992, 2021. e-Pub 2021. PMID: 35707737.
72. Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami S, Sharma P. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med 26(12):1845-1851, 2020. e-Pub 2020. PMID: 33046869.
73. Sharib J, Esserman L, Koay EJ, Maitra A, Shen Y, Kirkwood KS, Ozanne EM. Cost-effectiveness of Consensus Guideline Based Management of Pancreatic Cysts: The Sensitivity and Specificity Required for Guidelines to be Cost-Effective. Surgery 168(4):601-609, 2020. e-Pub 2020. PMID: 32739138.
74. Tamirisa N, Lin H, Shen Y, Shaitelman SF, Sri Karuturi M, Giordano SH, Babiera G, Bedrosian I. Association of Chemotherapy With Survival in Elderly Patients With Multiple Comorbidities and Estrogen Receptor-Positive, Node-Positive Breast Cancer. JAMA Oncol 6(10):1548--1554, 2020. e-Pub 2020. PMID: 32672820.
75. Pak D, Langohr K, Ning J, Martinez JC, Melis LG, Shen Y. Age Associated Coronavirus Disease 2019 Incubation Period: Impact on Quarantine Policy. MDPI: Mathematics 8(9), 2020. e-Pub 2020.
76. Lee CH, Zhou H, Ning J, Liu DD, Shen Y. CoxPhLb: An R Package for Analyzing Length-Biased Data under Cox Model. R Journal 12(1):118-130, 2020. e-Pub 2020. PMID: 33133648.
77. Shih YT, Shen Y. Time to Consider a Personalized Approach to Incorporate Tomosynthesis into Routine Breast Cancer Screening. J Natl Cancer Inst 112(6):553-554, 2020. e-Pub 2020. PMID: 31503277.
78. Ning J, Fouad TM, Lin H, Sahin AA, Lucci A, Woodward W, Krishnamurthy S, Tripathy D, Ueno NT, Shen Y. The impact of Ki-67 in the context of multidisciplinary care in primary inflammatory breast cancer. J Cancer 10(12):2635-2642, 2019. e-Pub 2019.
79. Huang X, Liu L, Ning J, Li L, Shen Y. Estimation of the Distribution of Longitudinal Biomarker Trajectories Prior to Disease Progression. Stat Med 38(11):2030-2046, 2019. e-Pub 2019. PMID: 30614014.
80. Lee CH, Ning J, Kryscio RJ, Shen Y. Analysis of combined incident and prevalent cohort data under a proportional mean residual life model. Stat Med 38(12):2103-2114, 2019. e-Pub 2019. PMID: 30680767.
81. Piao J, Ning J, Shen Y. Semiparametric Model for Bivariate Survival Data Subject to Biased Sampling. J R Stat Soc Ser B 81(2):409-429, 2019. e-Pub 2019. PMID: 31435191.
82. Shen Y, Dong W, Gulati R, Ryser MD, Etzioni R. Estimating the frequency of indolent breast cancer in screening trials. Stat Methods Med Res 28(4):1261-1271, 2019. e-Pub 2019. PMID: 29402176.
83. Tina Shih YC, Dong W, Xu Y, Shen Y. Assessing the Cost-Effectiveness of Updated Breast Cancer Screening Guidelines for Average-Risk Women from the American Cancer Society and US Preventive Services Task Force. Value Health 22(2):185-193, 2019. e-Pub 2019. PMID: 30711063.
84. Lee CH, Ning J, Shen Y. Model diagnostics for the proportional hazards model with length-biased data. Lifetime Data Anal 25:79-96, 2019. e-Pub 2019. PMID: 29450809.
85. Shen Y, Fujii T, Ueno NT, Tripathy D, Fu N, Zhou H, Ning J, Xiao L. Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: A network meta-analysis. Breast Cancer Res Treat 173(1):1-9, 2019. e-Pub 2019. PMID: 30242579.
86. Mao H, Li L, Yang W, Shen Y. On the propensity score weighting analysis with survival outcome: estimands, estimation and inference. Stat Med 37(26):3745-63, 2018. e-Pub 2018. PMID: 29855060.
87. Lee CH, Ning J, Shen Y. Analysis of Restricted Mean Survival Time for Length-Biased Data. Biometrics 74(2):575-583, 2018. e-Pub 2018. PMID: 28886217.
88. Woodward WA, Ueno NT, Kuerer HM, Lucci A, Shen Y. Reply to 'A standard mastectomy should not be the only recommended breast surgical treatment for non-metastatic inflammatory breast cancer: A large population-based study in the Surveillance, Epidemiology, and End Results database 18'. Breast 39:148-149, 2018. e-Pub 2018. PMID: 29729725.
89. Li L, Wu CH, Ning J, Huang X, Tina Shih YC, Shen Y. Semiparametric Estimation of Longitudinal Medical Cost Trajectory. J Am Stat Assoc 113(522):582-592, 2018. e-Pub 2018. PMID: 30853736.
90. Lin HY, Bedrosian I, Babiera GV, Shaitelman SF, Kuerer HM, Woodward WA, Ueno NT, Shen Y. Using the National Cancer Data Base for quality evaluation to assess adherence to treatment guidelines for nonmetastatic inflammatory breast cancer. Cancer 123(14):2618-2625, 2017. e-Pub 2017. PMID: 28295213.
91. Ning J, Hong C, Li L, Huang X, Shen Y. Estimating Treatment Effects in Observational Studies with Both Prevalent and Incident Cohorts. Can J Stat 45(2):202-219, 2017. e-Pub 2017. PMID: 29056817.
92. Liu H, Shen Y, Ning J, Qin J. Sample size calculations for prevalent cohort designs. Stat Methods Med Res 26(1):280-291, 2017. e-Pub 2017. PMID: 25091809.
93. Shen Y, Ning J, Qin J. Nonparametric and Semiparametric Regression Estimation for Length-biased Survival Data. Lifetime Data Anal 23(1):3-24, 2017. e-Pub 2017. PMID: 27086362.
94. Liu H, Ning J, Qin J and Shen Y. Semiparametric Maximum Likelihood Inference for Truncated or Biased-Sampling Data. Stat Sinica 26(3):1087-1115, 2016. e-Pub 2016.
95. Ning J, Peng S, Ueno N, Xu Y, Shih Y, Karuturi M, Giordano S, Shen Y. Has Racial Difference in Cause-Specific Death Improved in Older Patients with Late-Stage Breast Cancer?. Ann Oncol 26(10):2161-8, 2015. e-Pub 2015. PMID: 26223248.
96. Ahern CH, Shih YC, Dong W, Parmigiani G, Shen Y. Cost-Effectiveness of Alternative Strategies for Integrating MRI into Breast Cancer Screening for Women at High Risk. Br J Cancer 111(8):1542-51, 2014. e-Pub 2014. PMID: 25137022.
97. Ning J, Qin J, Shen Y. Score Estimating Equations from Embedded Likelihood Functions under Accelerated Failure Time Model. J Am Stat Assoc 109(508):1625-35, 2014. e-Pub 2014. PMID: 25663727.
98. Shih YC, Xu Y, Dong W, Smieliauskas F, Giordano S, Shen Y. First do no harm: population-based study shows non-evidence-based trastuzumab prescription may harm elderly women with breast cancer. Breast Cancer Res Treat 144(2):417-25, 2014. e-Pub 2014. PMID: 24557339.
99. Ning J, Qin J, Shen Y. Semiparametric accelerated failure time model for length-biased data with application to dementia study. Stat Sin 24(1):313-333, 2014. e-Pub 2014. PMID: 24478570.
100. Ng Tang D, Shen Y, Sun J, Wen S, Wolchok JD, Yuan J, Allison JP, Sharma P. Increased frequency of ICOS+ CD4 T-cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res 1(4):229-34, 2013. e-Pub 2013. PMID: 24777852.
101. Lynch SP, Shen Y, Kamat A, Grossman HB, Shah JB, Millikan RE, Dinney CP, Siefker-Radtke A. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic down-staging and long-term outcomes. Results from a retrospective study at the M. D. Anderson Cancer Center. Eur Urol 64(2):307-13, 2013. e-Pub 2013. PMID: 22564397.
102. Ning J, Qin J, Asgharian M, Shen Y. Empirical likelihood-based confidence intervals for length-biased data. Stat Med 32(13):2278-2291, 2013. e-Pub 2013. PMID: 23027662.
103. Cheng Y, Shen Y. An efficient sequential design of clinical trials. J Stat Plan Inference 143(2):283-295, 2013. e-Pub 2013. PMID: 23275685.
104. Shih, YCT, Chien, CR, Shen Y. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer. Breast Diseases 24(1):95-97, 2013. e-Pub 2013.
105. Brewster AM, Bedrosian I, Parker PA, Dong W, Peterson SK, Cantor SB, Crosby M, Shen Y. Association between contralateral prophylactic mastectomy and breast cancer outcomes by hormone receptor status. Cancer 118(22):5637-43, 2012. e-Pub 2012. PMID: 22517269.
106. Liu H, Qin J, Shen Y. Imputation for semiparametric transformation models with biased sampling data. Lifetime Data Anal 18(4):470-503, 2012. e-Pub 2012. PMID: 22903245.
107. Shen Y, Ning J, Qin J. Likelihood approaches for invariant density ratio model with biased-sampling data. Biometrika 99(2):363-378, 2012. e-Pub 2012. PMID: 23843663.
108. Ning J, Qin J, Shen Y. Buckley-James type Estimator with Right-censored and Length-biased Data. Biometrics 67(4):1369-78, 2011. e-Pub 2011. PMID: 21385160.
109. Qin J, Ning J, Liu H, Shen Y. Maximum likelihood estimations and EM algorithms with length-biased data. J Am Stat Assoc 106(496):1434-49, 2011. e-Pub 2011. PMID: 22323840.
110. Ahern CH, Cheng Y, Shen Y. Risk-specific optimal cancer screening schedules: an application to breast cancer early detection. Stat Biosci 3(2):169-186, 2011. e-Pub 2011. PMID: 22162743.
111. Ning J, Qin J, Shen Y. Nonparametric tests for right-censored data with biased sampling. J R Stat Soc Ser B 72(5):609-630, 2010. e-Pub 2010. PMID: 21031144.
112. Qin J, Shen Y. Statistical Methods for Analyzing Right-censored Length-biased Data under Cox Model. Biometrics 66(2):382-392, 2010. e-Pub 2010. PMID: 19522872.
113. Liu H, Shen Y. A Semiparametric Regression Cure Model for Interval-Censored Data. J Am Stat Assoc 104(487):1168-1178, 2009. e-Pub 2009. PMID: 20354594.
114. Shen Y, Ning J, Qin J. Analyzing Length-biased Data with Semiparametric Transformation and Accelerated Failure Time Models. J Am Stat Assoc 104(487):1192-1202, 2009. e-Pub 2009. PMID: 21057599.
115. Ahern CH, Shen Y. Cost-effectiveness analysis of mammography and clinical breast examination strategies: a comparison with current guidelines. Cancer Epidemiol Biomarkers Prev 18(3):718-725, 2009. e-Pub 2009. PMID: 19258473.
116. Shen Y, Dong W, Feig BW, Ravdin P, Theriault RL, Giordano SH. Patterns of treatment for early stage breast cancers at the M. D. Anderson Cancer Center from 1997 to 2004. Cancer 115(10):2041-2051, 2009. e-Pub 2009. PMID: 19288569.
117. Shen Y, Costantino JP, Qin J. Tamoxifen chemoprevention treatment and time to first diagnosis of estrogen receptor-negative breast cancer. J Natl Cancer Inst 100(20):1448-53, 2008. e-Pub 2008. PMID: 18840821.
118. Dong W, Berry DA, Bevers TB, Kau SW, Hsu L, Theriault RL, Shen Y. Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the university of Texas M.D. Anderson Cancer Center experience. Cancer Epidemiol Biomarkers Prev 17(5):1096-103, 2008. e-Pub 2008. PMID: 18483331.
119. Shen Y, Qin J, Costantino JP. Inference of Tamoxifen's Effects on Prevention of Breast Cancer from a Randomized Controlled Trial. J Am Stat Assoc 102(480):1235-1244, 2007. e-Pub 2007. PMID: 19662105.
120. Shen Y, Dong W, Esteva FJ, Kau SW, Theriault RL, Bevers TB. Are there racial differences in breast cancer treatments and clinical outcomes for women treated at M.D. Anderson Cancer Center?. Breast Cancer Res Treat 102(3):347-356, 2007. e-Pub 2007. PMID: 17028980.
121. Shen Y, Cheng Y. Adaptive Design: Estimation and Inference with Censored Data in a Semiparametric Model. Biostatistics 8:306-322, 2007. e-Pub 2007. PMID: 16787996.
122. Cong XJ, Yin G, Shen Y. Marginal Analysis of Correlated Failure Time Data with Informative Cluster Sizes. Biometrics 63(3):663-672, 2007. e-Pub 2007. PMID: 17825000.
123. Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, Bajorin DF, Reuter VE, Herr H, Old LJ, Sato E. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A 104(10):3967-72, 2007. e-Pub 2007. PMID: 17360461.
124. Beran M, Shen Y, Onida F, Wen S, Kantarjian H, Estey E. Prognostic significance of monocytosis in patients with myeloproliferative disorders. Leuk Lymphoma 47(3):417-23, 2006. e-Pub 2006. PMID: 16396764.
125. Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, Shen Y. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 295:299-305, 2006. e-Pub 2006. PMID: 16418465.
126. Zeng D, Cai J, Shen Y. Semiparameteric additive risks model for interval-censored data. Statistica Sinica 16:287-95, 2006. e-Pub 2006.
127. Sharma P, Shen Y, Wen S, Bajorin DF, Reuter VE, Old LJ, Jungbluth AA. Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res 12:5442-7, 2006. e-Pub 2006. PMID: 17000678.
128. Shen Y, Huang X. Nonparametric estimation of asymptomatic duration from a randomized prospective cancer screening trial. Biometrics 61(4):992-9, 2005. e-Pub 2005. PMID: 16401272.
129. Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 97(16):1195-203, 2005. e-Pub 2005. PMID: 16106024.
130. Yin G, Shen Y. Self-designing trial combined with classical group sequential monitoring. J Biopharm Stat 15:667-75, 2005. e-Pub 2005. PMID: 16022171.
131. Shen Y, Zelen M. Robust modeling in screening studies: estimation of sensitivity and preclinical sojourn time distribution. Biostatistics 6:604-14, 2005. e-Pub 2005. PMID: 15860542.
132. Shen Y, Parmigiani G. A model-based comparison of breast cancer screening strategies: mammograms and clinical breast examinations. Cancer Epidemiol Biomarkers Prev 14:529-32, 2005. e-Pub 2005. PMID: 15734983.
133. Handy BC, Shen Y. Evaluation of potassium values in a cancer patient population. LabMedicine 36:1-3, 2005. e-Pub 2005.
134. Cong XJ, Shen Y, Miller AB. Estimation of age-specific sensitivity and sojourn time in breast cancer screening studies. Stat Med 24:3123-38, 2005. e-Pub 2005. PMID: 15977269.
135. Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, Shen Y. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 293(7):810-6, 2005. e-Pub 2005. PMID: 15713770.
136. Bekele BN, Shen Y. A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial. Biometrics 61(2):343-54, 2005. e-Pub 2005. PMID: 16011680.
137. Cheng Y, Shen Y. Bayesian Adaptive Designs for Clinical Trials. Biometrika 92:633-646, 2005. e-Pub 2005.
138. Yin G, Shen Y. Adaptive design and estimation in randomized clinical trials with correlated observations. Biometrics 61:362-9, 2005. e-Pub 2005. PMID: 16011682.
139. Shen Y and Berry D. Re: Role of detection method in predicting breast cancer survival: Analysis of randomized screening trials (multiple letters). Journal of the National Cancer Institute 97(24):1853-1854, 2005. e-Pub 2005.
140. Davis DW, Shen Y, Mullani NA, Wen S, Herbst RS, O'Reilly M, Abbruzzese JL, McConkey DJ. Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. Clin Cancer Res 10:33-42, 2004. e-Pub 2004. PMID: 14734449.
141. Cheng Y, Shen Y. Estimation of a parameter and its exact confidence interval following sequential sample size reestimation trials. Biometrics 60:910-8, 2004. e-Pub 2004. PMID: 15606411.
142. Shen Y, Cai J. Sample size re-estimate for clinical trials with censored survival data. J Am Stat Assoc 98:418-426, 2003. e-Pub 2003.
143. Shen Y, Wu D, Zelen M. Testing the independence of two diagnostic tests. Biometrics 57:1009-17, 2001. e-Pub 2001. PMID: 11764239.
144. Shen Y, Zelen M. Screening sensitivity and sojourn time from breast cancer early detection clinical trials: mammograms and physical examinations. J Clin Oncol 19:3490-9, 2001. e-Pub 2001. PMID: 11481355.
145. Van Haaften-Day C, Shen Y, Xu F, Yu Y, Berchuck A, Havrilesky LJ, de Bruijn HW, van der Zee AG, Bast RC, Jr, Hacker NF. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer 92:2837-44, 2001. e-Pub 2001. PMID: 11753957.
146. Shen Y, Cai J. Maximum of the weighted Kaplan-Meier tests with application to cancer prevention and screening trials. Biometrics 57:837-43, 2001. e-Pub 2001. PMID: 11550935.
147. Giles FJ, Shen Y, Kantarjian HM, Korbling MJ, O'Brien S, Anderlini P, Donato M, Pierce S, Keating MJ, Freireich EJ, Estey E. Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival. Leuk Lymphoma 42:67-73, 2001. e-Pub 2001. PMID: 11699223.
148. Beran M, Shen Y, Kantarjian H, O'Brien S, Koller CA, Giles FJ, Cortes J, Thomas DA, Faderl S, Despa S, Estey EH. High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer 92:1999-2015, 2001. e-Pub 2001. PMID: 11596013.
149. Cai J, Shen Y. Permutation tests for comparing marginal survival functions with clustered failure time data. Stat Med 19:2963-73, 2000. e-Pub 2000. PMID: 11042626.
150. Estey EH, Shen Y, Thall PF. Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB. Blood 95:72-7, 2000. e-Pub 2000. PMID: 10607687.
151. Thall PF, Simon RM, Shen Y. Approximate Bayesian evaluation of multiple treatment effects. Biometrics 56:213-9, 2000. e-Pub 2000. PMID: 10783798.
152. Shen Y, Fisher L. Statistical inference for self-designing clinical trials with a one-sided hypothesis. Biometrics 55:190-7, 1999. e-Pub 1999. PMID: 11318154.
153. Shen Y, Zelen M. Estimation procedures for screening programs: Stable and nonstable disease models for multi-modality case finding. Biometrika 86:503-515, 1999. e-Pub 1999.
154. Shen Y, Cheng SC. Confidence bands for cumulative incidence curves under the additive risk model. Biometrics 55:1093-100, 1999. e-Pub 1999. PMID: 11315053.
155. Shen Y, Fleming TR. Assessing effects on long-term survival after early termination of randomized trials. Lifetime Data Anal 5:55-66, 1999. e-Pub 1999. PMID: 10214002.
156. Shen Y, Thall PF. Parametric likelihoods for multiple non-fatal competing risks and death. Stat Med 17:999-1015, 1998. e-Pub 1998. PMID: 9612887.
157. Shen Y, Fleming TR. Weighted mean survival test statistics: a class of distance tests for censored survival data. J R Stat Soc Ser B 59:269-280, 1997. e-Pub 1997.
158. Shen Y, Fleming TR. Large sample properties for some survival estimators in heterogeneous samples. J Stat Plan Inference 60:123-138, 1997. e-Pub 1997.
159. Etzioni R, Shen Y. Estimating asymptomatic duration in cancer: the AIDS connection. Stat Med 16:627-44, 1997. e-Pub 1997. PMID: 9131752.
160. Midis GP, Shen Y, Owen-Schaub LB. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Research 56:3870-4, 1996. e-Pub 1996. PMID: 8752148.
161. Etzioni R, Shen Y, Petteway JC, Brawer MK. Age-specific prostate-specific antigen: a reassessment. Prostate Suppl 7:70-7, 1996. e-Pub 1996. PMID: 8950367.

Other Articles

1. Fujii T, Iwase T, Shen Y, Fukui J, Ueno NT Reconsidering the definition of triple-negative breast cancer in the immune checkpoint inhibitor era: an optimal cut-off value for hormone receptor percentage of HER2-negative invasive breast cancer. British Journal of Cancer.

Abstracts

1. Shen Y. Margins < 2 mm for patients with ductal carcinoma in situ and contraindication for breast conservation with radiotherapy. Poster Session: Breast Cancer‹Local/Regional/Adjuvant, 2017. e-Pub 2017.
2. Shen Y. USE OF RELATIVE RISK RATIOS TO PRESENT UNCERTAINTY IN MICROSIMULATION MODELS WITH MULTIPLE COMPARATORS: AN APPLICATION TO BREAST CANCER SCREENING STRATEGIES, 2017. e-Pub 2017.
3. Shen Y. Estimation of cancer natural history and overdiagnosis from cancer screening trials. Monthly Biostatistics Seminar, 2017. e-Pub 2017.
4. Moreno, A, Lin HY, Bedrosian I, Smith B, Babiera G, Stauder M, Buchholz T, Woodward W, Shen Y, Shaitelman S. Effect of adjuvant radiation therapy with or without regional node irradiation on overall survival in patients with high-risk invasive breast cancer: A National Cancer Database Analysis, 2016. e-Pub 2016.
5. Menen RS, Lin HY, Shen Y, Shaitelman S, Bedrosian I, Woodward W, Ueno N, Valero V, Babiera G. Resection of the primary tumor substantially improves median overall survival in patients with Stage IV metastatic inflammatory breast cancer. Proceedings of the Society of Surgical Oncology 69th Annual Cancer Symposium, Boston, MA March 2-5, 2016 (Poster Presentation, Abstract #2373536), 2016. e-Pub 2016.
6. Brewster AM, Peterson SK, Bedrosian I, Dong W, Cantor SB, Volk RJ, DuPont H, Shen Y, Parker P. Psychosocial Predictors of Decision Making for Contralateral Prophylactic Mastectomy. e-Pub 2016.
7. Barcenas C; Sinha A; Raghavendra A; Syed M; Hsu L; Patangan M; Chavez-Mac Gregor M; Shen Y; Giordano S; Ueno N; Valero V; Tripathy D. Outcomes after chemotherapy in early-stage breast >cancer (EBC) patients who underwent a 21-gene expression assay. e-Pub 2016.
8. Fujii T; Kogawa T; Dong W; Litton J; Moulder S; Tripathy D; Hunt K; Iwamoto T; Pusztai L; Lim B; Shen Y; Ueno N. New threshold of ER positivity in early stage HER2- breast cancer. e-Pub 2016.
9. Tina Shih Y; Dong W; Xu Y; Shen Y. Assessing the Cost-Effectiveness of the American Cancer Society’s Updated Breast Cancer Screening Guideline for Women at Average Risk. e-Pub 2016.
10. Colfry J, Lin H, Shen Y, Kuerer H, Shaitelman S, Babiera G, Bedrosian I. Patterns of Axillary Surgery in DCIS Patients Within the US National Cancer Database. Proceedings of the American Society of Breast Surgeons 16th Annual Meeting in Orlando, FL. April 29 - May 3, 2015 (Poster Presentation, Abstract #2145010). JAMA Surgery, 2015. e-Pub 2015.
11. Colfry AJ, Lin H, Shen Y, Kuerer HM, Shaitelman S, Babiera GV, Bedrosian I. Factors Associated with DCIS diagnosis: A Population Based Review of the National Cancer Database. Proceedings of the Society of Surgical Oncology 68th Annual Cancer Symposium, Houston, TX March 25-28, 2015 (Poster Presentation, Abstract # 2092577). Jama Surgery, 2015. e-Pub 2015.
12. Loveland-Jones C, Shaitelman S, Lin H, Shen Y, Bedrosian I, Kuerer HM, Babiera GV. Disparities in the Use of Post-Mastectomy Radiation Therapy for Inflammatory Breast Cancer. Proceedings of the Society of Surgical Oncology 68th Annual Cancer Symposium, Houston, TX March 25-28, 2015 (Poster Presentation, Abstract # 2086390), 2015. e-Pub 2015.
13. Lautner MA, Lin H, Shen Y, Parker C, Kuerer HM, Shaitelman S, Babiera G, Bedrosian I. Disparities in utilization of breast-conserving therapy among breast cancer patients. Proceedings of the 2014 ASCO Breast Cancer Symposium, San Francisco CA September 4-6, 2014 (Abstract # 104), 2014. e-Pub 2014.
14. Lautner M, Parker C, Lin H, Shen Y, Kuerer H, Shaitelman S, Babiera G, Bedrosian I. National Trends in Mastectomy Rates from 1998 to 2010. Proceedings of the Society of Surgical Oncology 67th Annual Cancer Symposium, Phoenix, AZ March 12-15, 2014 (Poster Session, Abstract #1850921), 2014. e-Pub 2014.
15. Reuth NM, Lin HY, Bedrosian I, Shaitelman SF, Ueno NT, Shen Y, Babiera G. Underuse of Tri-Modality Treatment Impacts Survival for Patients with Inflammatory Breast Cancer: An Analysis of Treatment and Survival Trends from The National Cancer Database. Proceedings of the Society of Surgical Oncology 67th Annual Cancer Symposium, Phoenix, AZ March 12-15, 2014 (Poster Session, Abstract # 1837679), 2014. e-Pub 2014.
16. Shaitelman SF, Lin H, Shen Y, Bedrosian I, Bloom ES, Babiera G. Utilization of Accelerated Partial Breast Irradiation (APBI) and Guidline Concordance: Analysis of the National Cancer Database. Proceedings of the ASCO 2013 Breast Cancer Symposium, San Francisco, CA September 7-9, 2013 (Abstract # 119569), 2013. e-Pub 2013.
17. Shen Y. Adaptive designs in clinical trials. Joint Statistical Meeting (JSM), 2006. e-Pub 2006.
18. Shen Y. Bayesian Adaptive Designs for Clinical Trials. Joint Statistical Meeting (JSM), 2005. e-Pub 2005.
19. Shen, Parmigiani Y, Giovanni. Optimization of Breast Cancer Screening. Probability, Statistics and Modeling in Public Health, Workshop in Honor of Marvin Zelen, 2003. e-Pub 2003.
20. Shen Y. Statistical inference for self-designing clinical trials. Joint Statistical Meeting (JSM), 2001. e-Pub 2001.
21. Shen Y. Early Detection for Breast Cancer: How Much can Clinical Breast Examinations Add to Mammography?. International Biometric Society (ENAR), 2001. e-Pub 2001.
22. Shen Y, Zelen M. Estimations of screening sensitivity and sojourn time distributions. Biometrika, 2000. e-Pub 2000.
23. Shen Y, Fleming TR. Weighted mean survival test statistics: a class of distance tests for censored survival data. J R Stat Soc Ser B(Ser B 59:269-280,), 1997. e-Pub 1997.
24. Shen Y Fleming T. Mean survival estimator, with applications for two-sample test. Joint American Statistical Association Meetings, 1995. e-Pub 1995.
25. HM Kuerer HM, GM Rauch GM, S Krishnamurthy S, EJ Diego EJ, WT Yang WT, Shen Y, Lin H, Lucci A, DL Ramirez DL, TW Moseley TW, JA Mouabbi JA, Boughey JC, SF Shaitelman SF, White RL, KH Hunt KH, MP Mitchell MP, MT Teshome MT, HM Johnson HM, BD Smith BD, Valero AV. Omission of breast surgery after neoadjuvant systemic therapy for invasive cancer: three-year preplanned primary-endpoint on a phase 2 multicentre prospective trial.

Book Chapters

1. Singh P, Shen Y, Hunt K. Trial Design: Overview of Study Designs. In: Clinical Trials. Springer International Publishing, 37-45, 2020.
2. Shen Y, Parmigianni G. Optimization of breast cancer screening strategies. In: Probability, Statistics and Modeling in Public Health. Springer Science and Business Media, Inc, 405-420, 2006.
3. Grossman BH, Sabichi AL, Shen Y. Bladder Cancer: Clinical strategies for cancer chemoprevention. In: Cancer Chemoprevention: Strategies for Cancer Chemoprevention, 315-322, 2005.